{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T09:48:59Z","timestamp":1777888139153,"version":"3.51.4"},"reference-count":109,"publisher":"SAGE Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["PRM"],"published-print":{"date-parts":[[2021,9,28]]},"abstract":"<jats:p>Anti-N-Methyl-D-Aspartate Receptor Encephalitis (ANMDARE) is one of the most common autoimmune encephalitis in the pediatric population. Patients with ANMDARE initially present with a prodrome of neuropsychiatric symptoms followed by progressively worsening seizures, agitation, and movement disorders. Complications can include problems such as aggression, insomnia, catatonia, and autonomic instability. Due to the complexity of this disease process, symptom management can be complex and may lead to significant polypharmacy. The goal of this review is to educate clinicians about the challenges of managing this disorder and providing guidance in symptom management.<\/jats:p>","DOI":"10.3233\/prm-200677","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T14:28:42Z","timestamp":1630420122000},"page":"333-343","source":"Crossref","is-referenced-by-count":2,"title":["A narrative review of pharmacologic approaches to symptom management of pediatric patients diagnosed with anti-NMDA receptor encephalitis"],"prefix":"10.1177","volume":"14","author":[{"given":"Joshua A.","family":"Vova","sequence":"first","affiliation":[{"name":"Department of Physiatry, Children\u2019s Healthcare of Atlanta, Johnson Ferry Rd NE. Atlanta, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"issue":"1","key":"10.3233\/PRM-200677_ref1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/ana.21050","article-title":"Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma","volume":"61","author":"Dalmau","year":"2007","journal-title":"Ann Neurol"},{"issue":"7","key":"10.3233\/PRM-200677_ref2","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s10096-009-0799-0","article-title":"The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the california encephalitis project","volume":"54","author":"Gable","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.3233\/PRM-200677_ref3","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(08)70224-2","article-title":"Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies","volume":"7","author":"Dalmau","year":"2008","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.3233\/PRM-200677_ref4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: An observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.3233\/PRM-200677_ref5","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00415-017-8407-1","article-title":"Differences in treatment of anti-NMDA receptor encephalitis: results of a worldwide survey","volume":"264","author":"Bartolini","year":"2017","journal-title":"J Neurol"},{"issue":"5","key":"10.3233\/PRM-200677_ref6","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.pediatrneurol.2014.01.012","article-title":"Pediatric anti-NMDA (N-methyl D-Aspartate) receptor encephalitis","volume":"50","author":"Salvucci","year":"2014","journal-title":"Pediatr Neurol"},{"issue":"7","key":"10.3233\/PRM-200677_ref7","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.braindev.2016.01.009","article-title":"Plasma exchange in pediatric anti-NMDAR encephalitis: A systematic review","volume":"38","author":"Suppiej","year":"2016","journal-title":"Brain Dev"},{"issue":"4","key":"10.3233\/PRM-200677_ref8","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ejpn.2015.02.006","article-title":"Paediatric anti-N-methyl-d-aspartate receptor encephalitis: The first Italian multicenter case series","volume":"19","author":"Sartori","year":"2015","journal-title":"Eur J Paediatr Neurol"},{"issue":"2","key":"10.3233\/PRM-200677_ref9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.cppeds.2015.11.005","article-title":"Anti-N-Methyl-d-Aspartate Receptor-Mediated Encephalitis: Recent Advances in Diagnosis and Treatment in Children","volume":"46","author":"Ryan","year":"2016","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"issue":"5","key":"10.3233\/PRM-200677_ref10","doi-asserted-by":"publisher","first-page":"e280","DOI":"10.1212\/NXI.0000000000000280","article-title":"Neuroleptic intolerance in patients with anti-NMDAR encephalitis","volume":"3","author":"Lejuste","year":"2016","journal-title":"Neurol - Neuroimmunol Neuroinflammation"},{"issue":"January","key":"10.3233\/PRM-200677_ref11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jneuroim.2017.09.005","article-title":"Anti-N-methyl-D-aspartate receptor encephalitis in children of Central South China: Clinical features, treatment, influencing factors, and outcomes","volume":"312","author":"Wang","year":"2017","journal-title":"J Neuroimmunol"},{"key":"10.3233\/PRM-200677_ref12","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.3892\/etm.2018.6329","article-title":"Clinical diagnosis and treatment of pediatric anti-N-methyl-D-aspartate receptor encephalitis: A single center retrospective study","volume":"16","author":"Sai","year":"2018","journal-title":"Exp Ther Med"},{"issue":"2","key":"10.3233\/PRM-200677_ref13","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jns.2017.04.007","article-title":"Comparisons between Psychiatric Symptoms of Patients with Anti-NMDAR Encephalitis and New-Onset Psychiatric Patients","volume":"75","author":"Wang","year":"2018","journal-title":"Neuropsychobiology"},{"issue":"3","key":"10.3233\/PRM-200677_ref14","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/acn.12013","article-title":"Psychiatric phenomena as initial manifestation of encephalitis by anti-NMDAR antibodies","volume":"25","author":"Maat","year":"2013","journal-title":"Acta Neuropsychiatr"},{"issue":"1","key":"10.3233\/PRM-200677_ref15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1176\/appi.neuropsych.17120343","article-title":"The Psychiatric Phenotype of Anti-NMDA Receptor Encephalitis","volume":"31","author":"Gibson","year":"2019","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"1","key":"10.3233\/PRM-200677_ref16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/ana.21756.Anti","article-title":"Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents","volume":"66","author":"Florance","year":"2009","journal-title":"Ann Neurol"},{"key":"10.3233\/PRM-200677_ref17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/hup","article-title":"Neurological Complications of Psychiatric Drugs: clinical features and management","volume":"23","author":"Haddad","year":"2008","journal-title":"Hum Psychopharmacol Clin Exp"},{"issue":"4","key":"10.3233\/PRM-200677_ref18","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/dmcn.12882","article-title":"Symptomatic treatment of children with anti-NMDAR encephalitis","volume":"58","author":"Mohammad","year":"2016","journal-title":"Dev Med Child Neurol"},{"issue":"12","key":"10.3233\/PRM-200677_ref19","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/mds.25999","article-title":"Movement disorders in children with anti-NMDAR encephalitis and other autoimmune encephalopathies","volume":"29","author":"Mohammad","year":"2014","journal-title":"Mov Disord"},{"issue":"0","key":"10.3233\/PRM-200677_ref20","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/j.pediatrneurol.2017.03.010","article-title":"Extended clinical spectrum of Anti NMDA receptor encephalitis in children: A case series","volume":"71","author":"Goenka","year":"2017","journal-title":"Pediatr Neurol"},{"issue":"1","key":"10.3233\/PRM-200677_ref21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S1474-4422(10)70253-2","article-title":"Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis","volume":"10","author":"Dalmau","year":"2011","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.3233\/PRM-200677_ref22","doi-asserted-by":"publisher","first-page":"S256","DOI":"10.1016\/j.apmr.2015.01.025","article-title":"Psychotropic medication use during inpatient rehabilitation for traumatic brain injury","volume":"96","author":"Hammond","year":"2015","journal-title":"Arch Phys Med Rehabil"},{"issue":"1003","key":"10.3233\/PRM-200677_ref23","doi-asserted-by":"publisher","first-page":"6119","DOI":"10.1196\/annals.1300.008","article-title":"NMDA receptor hypofunction model of psychosis","volume":"6","author":"Farber","year":"2003","journal-title":"Ann NY Acad Sci"},{"issue":"4","key":"10.3233\/PRM-200677_ref24","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.genhosppsych.2014.02.010","article-title":"Management of psychiatric symptoms in anti-NMDAR encephalitis: A case series, literature review and future directions","volume":"36","author":"Kuppuswamy","year":"2014","journal-title":"Gen Hosp Psychiatry"},{"issue":"3-4","key":"10.3233\/PRM-200677_ref25","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.brainresbull.2010.04.006","article-title":"N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: The final common pathway on the road to schizophrenia?","volume":"83","author":"Kantrowitz","year":"2010","journal-title":"Brain Res Bull"},{"issue":"1","key":"10.3233\/PRM-200677_ref26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.rehab.2015.11.001","article-title":"Care management of the agitation or aggressiveness crisis in patients with TBI. Systematic review of the literature and practice recommendations","volume":"59","author":"Luaut\u00e9","year":"2016","journal-title":"Ann Phys Rehabil Med"},{"issue":"3","key":"10.3233\/PRM-200677_ref27","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1176\/appi.ajp.2010.10020181","article-title":"Anti-NMDA Receptor Encephalitis: Diagnosis, Psychiatric Presentation, and Treatment","volume":"168","author":"Chapman","year":"2011","journal-title":"Am J Psychiatry"},{"key":"10.3233\/PRM-200677_ref28","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.cca.2014.08.010","article-title":"Autoimmune NMDA receptor encephalitis","volume":"438","author":"Lazar-Molnar","year":"2015","journal-title":"Clin Chim Acta"},{"issue":"17-18","key":"10.3233\/PRM-200677_ref29","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.lfs.2008.08.007","article-title":"Administration of haloperidol and risperidone after neurobehavioral testing hinders the recovery of traumatic brain injury-induced deficits","volume":"83","author":"Hoffman","year":"2008","journal-title":"Life Sci"},{"issue":"2","key":"10.3233\/PRM-200677_ref30","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1089\/neu.2016.4417","article-title":"Combining the Antipsychotic Drug Haloperidol and Environmental Enrichment after Traumatic Brain Injury Is a Double-Edged Sword","volume":"34","author":"Folweiler","year":"2017","journal-title":"J Neurotrauma"},{"issue":"5","key":"10.3233\/PRM-200677_ref31","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1212\/wnl.45.5.865","article-title":"Common drugs may influence motor recovery after stroke","volume":"45","author":"Goldstein","year":"1995","journal-title":"The Sygen In Acute Stroke Study Investigators. Neurology"},{"issue":"10","key":"10.3233\/PRM-200677_ref32","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1089\/cap.2016.0102","article-title":"Agitation Management in Pediatric Males with Anti-N-Methyl-D-Aspartate Receptor Encephalitis","volume":"26","author":"Schumacher","year":"2016","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"9","key":"10.3233\/PRM-200677_ref33","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1089\/cap.2015.0093","article-title":"Evaluation of the safety of quetiapine in treating delirium in critically ill children: A retrospective review","volume":"25","author":"Joyce","year":"2015","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"10.3233\/PRM-200677_ref34","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/JCP.0b013e3182549259","article-title":"Adverse effects of second-generation antipsychotics in children and adolescents: A bayesian meta-analysis","volume":"32","author":"Cohen","year":"2012","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"10.3233\/PRM-200677_ref35","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1682\/JRRD.2008.09.0120","article-title":"Pharmacological management of neurobehavioral disorders following traumatic brain injury\u2013a state-of-the-art review","volume":"46","author":"Chew","year":"2009","journal-title":"J Rehabil Res Dev"},{"issue":"9","key":"10.3233\/PRM-200677_ref36","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1080\/02699050600743972","article-title":"The impact of acute care medications on rehabilitation outcome after traumatic brain injury","volume":"20","author":"Mysiw","year":"2006","journal-title":"Brain Inj"},{"issue":"1","key":"10.3233\/PRM-200677_ref37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.rehab.2015.10.003","article-title":"Non pharmacological treatments for psychological and behavioural disorders following traumatic brain injury (TBI)","volume":"59","author":"Plantier","year":"2016","journal-title":"A systematic literature review and expert opinion leading to recommendations. Ann Phys Rehabil Med"},{"issue":"7","key":"10.3233\/PRM-200677_ref38","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/S1474-4422(15)00068-X","article-title":"Sleep-wake disturbances after traumatic brain injury","volume":"14","author":"Ouellet","year":"2015","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.3233\/PRM-200677_ref39","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1097\/CCM.0000000000003268","article-title":"Critical Care Management of Anti-N-Methyl-d- Aspartate Receptor Encephalitis","volume":"46","author":"Neyens","year":"2018","journal-title":"Crit Care Med"},{"key":"10.3233\/PRM-200677_ref40","doi-asserted-by":"crossref","unstructured":"Fleminger S , Greenwood RR , Oliver DL . Pharmacological management for agitation and aggression in people with acquired brain injury. Cochrane Database Syst Rev. 2006;(1).","DOI":"10.1002\/14651858.CD003299.pub2"},{"issue":"1","key":"10.3233\/PRM-200677_ref41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2788.2009.01232.x","article-title":"Pharmacotherapy for aggressive behaviours in persons with intellectual disabilities: Treatment or mistreatment?","volume":"54","author":"Tsiouris","year":"2010","journal-title":"J Intellect Disabil Res"},{"issue":"6","key":"10.3233\/PRM-200677_ref42","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/0026-0495(91)90053-y","article-title":"Reduced Metabolic Rate During B-Adrenergic Blockade in Humans","volume":"40","author":"Welle","year":"1991","journal-title":". Metabolism"},{"issue":"10","key":"10.3233\/PRM-200677_ref43","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/archneur.61.10.1625-b","article-title":"Paroxysmal autonomic instability after brain injury","volume":"61","author":"Rabinstein","year":"2004","journal-title":"Arch Neurol"},{"issue":"2","key":"10.3233\/PRM-200677_ref44","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ejpn.2018.01.012","article-title":"Pediatric NMDAR encephalitis: A single center observation study with a closer look at movement disorders","volume":"22","author":"Granata","year":"2018","journal-title":"Eur J Paediatr Neurol"},{"issue":"2","key":"10.3233\/PRM-200677_ref45","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12028-007-9021-3","article-title":"A critical review of the pathophysiology of dysautonomia following traumatic brain injury","volume":"8","author":"Baguley","year":"2008","journal-title":"Neurocrit Care"},{"issue":"2","key":"10.3233\/PRM-200677_ref46","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2174\/156802607779318190","article-title":"Interest of alpha2-adrenergic agonists and antagonists in clinical practice: background, facts and perspectives","volume":"7","author":"Crassous","year":"2007","journal-title":"Curr Top Med Chem"},{"issue":"11","key":"10.3233\/PRM-200677_ref47","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S1364-6613(98)01240-6","article-title":"Catecholamine modulation of prefrontal cortical cognitive function","volume":"2","author":"Arnsten","year":"1998","journal-title":"Trends Cogn Sci"},{"key":"10.3233\/PRM-200677_ref48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/aic","article-title":"Guanfacine\u2019s Mechanism of Action in Treating Prefrontal Cortical Disorders: Successful Translation Across Species","volume":"176","author":"Arnsten","year":"2020","journal-title":"Neurobiol Learn Mem"},{"issue":"2","key":"10.3233\/PRM-200677_ref49","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1089\/cap.2018.0121","article-title":"Rating of the effectiveness of 26 psychiatric and seizure medications for autism spectrum disorder: Results of a national survey","volume":"29","author":"Coleman","year":"2019","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"10.3233\/PRM-200677_ref50","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.ejpn.2017.11.010","article-title":"Principles and approaches to the treatment of immune-mediated movement disorders","volume":"22","author":"Mohammad","year":"2018","journal-title":"Eur J Paediatr Neurol"},{"key":"10.3233\/PRM-200677_ref51","unstructured":"Kruse JL , et al. Anti- N -methyl- D -aspartate receptor encephalitis: A targeted review of clinical presentation,diagnosis, and approaches to psychopharmacologic management 2014;26(2):111\u20139."},{"issue":"4","key":"10.3233\/PRM-200677_ref52","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.ccc.2008.06.001","article-title":"Neurobehavioral Management of Traumatic Brain Injury in the Critical Care Setting","volume":"24","author":"Arciniegas","year":"2008","journal-title":"Crit Care Clin"},{"key":"10.3233\/PRM-200677_ref53","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.brainres.2012.04.032","article-title":"Buspirone: What is it all about?","volume":"1461","author":"Loane","year":"2012","journal-title":"Brain Res"},{"issue":"4","key":"10.3233\/PRM-200677_ref54","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/00001199-200208000-00006","article-title":"Serotonin agents in the treatment of acquired brain injury","volume":"17","author":"Zafonte","year":"2002","journal-title":"J Head Trauma Rehabil"},{"issue":"2","key":"10.3233\/PRM-200677_ref55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/14651858.CD003499.pub3","article-title":"Antiepileptics for aggression and associated impulsivity (Review)","author":"Huband","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.3233\/PRM-200677_ref56","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.psym.2015.09.008","article-title":"Valproic Acid for Treatment of Hyperactive or Mixed Delirium: Rationale and Literature Review","volume":"56","author":"Sher","year":"2015","journal-title":"Psychosomatics"},{"issue":"10","key":"10.3233\/PRM-200677_ref57","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1080\/02699050701559558","article-title":"Pharmacological management of neurobehavioural sequelae of traumatic brain injury: A survey of current physiatric practice","volume":"21","author":"Francisco","year":"2007","journal-title":"Brain Inj"},{"issue":"6","key":"10.3233\/PRM-200677_ref58","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1093\/brain\/awq113","article-title":"N-methyl-d-aspartate antibody encephalitis: Temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes","volume":"133","author":"Irani","year":"2010","journal-title":"Brain"},{"issue":"65","key":"10.3233\/PRM-200677_ref59","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.seizure.2018.12.015","article-title":"EEG findings in NMDA encephalitis - A systematic review","author":"Gillinder","year":"2019","journal-title":"Seizure:Eur J Epilepsy"},{"key":"10.3233\/PRM-200677_ref60","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1212\/WNL.0b013e3182698cd8","article-title":"Extreme Delta Brush:A unique EEG pattern in adults with anti-NMDA receptor encephalitis","volume":"79","author":"Schmitt","year":"2012","journal-title":"Neurology"},{"key":"10.3233\/PRM-200677_ref61","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.3233\/PRM-200677_ref62","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1177\/1550059417693168","article-title":"Delta Brush Pattern Is Not Unique to NMDAR Encephalitis: Evaluation of Two Independent Long-Term EEG Cohorts","volume":"49","author":"Baykan","year":"2018","journal-title":"Clin EEG Neurosci"},{"issue":"1","key":"10.3233\/PRM-200677_ref63","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1176\/appi.ajp.159.1.109","article-title":"EEG Abnormalities During Treatment With Typical and Atypical Antipsychotics","volume":"159","author":"Centorrino","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.3233\/PRM-200677_ref64","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8749.2009.03542.x"},{"issue":"4","key":"10.3233\/PRM-200677_ref65","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/00001199-200208000-00007","article-title":"Sleep disturbances and their management in patients with brain injury","volume":"17","author":"Thaxton","year":"2002","journal-title":"J Head Trauma Rehabil"},{"issue":"2","key":"10.3233\/PRM-200677_ref66","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ejpn.2014.12.007","article-title":"Current role of melatonin in pediatric neurology: Clinical recommendations","volume":"19","author":"Bruni","year":"2015","journal-title":"Eur J Paediatr Neurol"},{"issue":"4","key":"10.3233\/PRM-200677_ref67","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.chc.2012.08.001","article-title":"Pediatric Sleep Pharmacology","volume":"21","author":"Pelayo","year":"2012","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"issue":"2","key":"10.3233\/PRM-200677_ref68","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.psym.2018.11.009","article-title":"Acute Pharmacological Management of Behavioral and Emotional Dysregulation Following a Traumatic Brain Injury: A Systematic Review of the Literature","volume":"60","author":"Nash","year":"2019","journal-title":"Psychosomatics"},{"issue":"5","key":"10.3233\/PRM-200677_ref69","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.pmrj.2011.04.010","article-title":"Managing sleepiness after traumatic brain injury","volume":"3","author":"Greenwald","year":"2011","journal-title":"PM R"},{"issue":"6","key":"10.3233\/PRM-200677_ref70","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1542\/peds.2006-2773","article-title":"Use of sleep medications in hospitalized pediatric patients","volume":"119","author":"Meltzer","year":"2007","journal-title":"Pediatrics"},{"issue":"1","key":"10.3233\/PRM-200677_ref71","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.rehab.2015.10.003","article-title":"Drugs for behavior disorders after traumatic brain injury: Systematic review and expert consensus leading to French recommendations for good practice","volume":"59","author":"Plantier","year":"2016","journal-title":"Ann Phys Rehabil Med"},{"issue":"9","key":"10.3233\/PRM-200677_ref72","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/apa.12315","article-title":"Management strategies and medication use for treating paediatric patients with concussions","volume":"102","author":"Kinnaman","year":"2013","journal-title":"Acta Paediatr Int J Paediatr"},{"issue":"11","key":"10.3233\/PRM-200677_ref73","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11910-017-0792-4","article-title":"Sleep Disturbance After TBI","volume":"17","author":"Barshikar","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"3","key":"10.3233\/PRM-200677_ref74","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ridd.2010.12.035","article-title":"Pharmacological treatment of sleep disturbance in developmental disabilities: A review of the literature","volume":"32","author":"Hollway","year":"2011","journal-title":"Res Dev Disabil"},{"issue":"3","key":"10.3233\/PRM-200677_ref75","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1055\/s-0034-1396802","article-title":"Low risk for switch to mania during treatment with sleep promoting antidepressants","volume":"48","author":"Wichniak","year":"2015","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"10.3233\/PRM-200677_ref76","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00001199-200701000-00009","article-title":"Pharmacological treatment of insomnia for individuals with brain injury","volume":"22","author":"Flanagan","year":"2007","journal-title":"J Head Trauma Rehabil"},{"issue":"2","key":"10.3233\/PRM-200677_ref77","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.spen.2015.03.002","article-title":"Pediatric Sleep Pharmacology: A Primer","volume":"22","author":"Troester","year":"2015","journal-title":"Semin Pediatr Neurol"},{"issue":"1","key":"10.3233\/PRM-200677_ref78","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/HTR.0b013e3181c1d1e1","article-title":"The effect of sleep medications on cognitive recovery from traumatic brain injury","volume":"25","author":"Larson","year":"2010","journal-title":"J Head Trauma Rehabil"},{"key":"10.3233\/PRM-200677_ref79","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.brainres.2016.01.021","article-title":"Pharmacotherapy in rehabilitation of post-acute traumatic brain injury","volume":"1640","author":"Bhatnagar","year":"2016","journal-title":"Brain Res"},{"issue":"8","key":"10.3233\/PRM-200677_ref80","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1177\/0269881111424455","article-title":"Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: A prospective placebo-controlled study","volume":"26","author":"Roehrs","year":"2012","journal-title":"J Psychopharmacol"},{"issue":"4","key":"10.3233\/PRM-200677_ref81","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1136\/jnnp.65.4.436","article-title":"Dystonia and chorea in acquired systemic disorders","volume":"65","author":"Janavs","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.3233\/PRM-200677_ref82","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ocl.2010.06.001","article-title":"Assessment and treatment of movement disorders in children with cerebral palsy","volume":"41","author":"Deon","year":"2010","journal-title":"Orthop Clin North Am"},{"issue":"7","key":"10.3233\/PRM-200677_ref83","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/mds.25552","article-title":"Medical treatment of dystonia","volume":"28","author":"Jankovic","year":"2013","journal-title":"Mov Disord"},{"issue":"1","key":"10.3233\/PRM-200677_ref84","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1021\/acschemneuro.8b00304","article-title":"N-Methyl- d -aspartate Receptor Antibody Encephalitis: A Concise Review of the Disorder, Diagnosis, and Management","volume":"10","author":"Staley","year":"2019","journal-title":"ACS Chem Neurosci"},{"key":"10.3233\/PRM-200677_ref85","doi-asserted-by":"publisher","DOI":"10.1016\/j.spen.2021.100873"},{"issue":"9","key":"10.3233\/PRM-200677_ref86","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.pmrj.2009.07.014","article-title":"Role of Oral Medications in Spasticity Management","volume":"1","author":"Watanabe TK","year":"2009","journal-title":"PM R"},{"issue":"10","key":"10.3233\/PRM-200677_ref87","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.3109\/02699052.2013.804202","article-title":"Spasticity after stroke: Physiology, assessment and treatment","volume":"27","author":"Thibaut","year":"2013","journal-title":"Brain Inj"},{"issue":"2","key":"10.3233\/PRM-200677_ref88","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/00001199-200403000-00002","article-title":"Acute Care Management of Post-TBI Spasticity","volume":"19","author":"Zafonte","year":"2004","journal-title":"J Head Trauma Rehabil"},{"issue":"9","key":"10.3233\/PRM-200677_ref89","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00381-007-0396-4","article-title":"Nonoperative management of spasticity in children","volume":"23","author":"Ronan","year":"2007","journal-title":"Childs Nerv Syst"},{"issue":"1","key":"10.3233\/PRM-200677_ref90","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ejpn.2015.09.007","article-title":"Gabapentin can significantly improve dystonia severity and quality of life in children","volume":"20","author":"Liow","year":"2016","journal-title":"Eur J Paediatr Neurol"},{"issue":"1","key":"10.3233\/PRM-200677_ref91","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.pmr.2014.09.008","article-title":"Pediatric Tone Management","volume":"26","author":"Vadivelu","year":"2015","journal-title":"Phys Med Rehabil Clin N Am"},{"issue":"2","key":"10.3233\/PRM-200677_ref92","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1136\/jnnp-2011-300411","article-title":"Cognitive deficits following anti-NMDA receptor encephalitis","volume":"83","author":"Finke","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"10.3233\/PRM-200677_ref93","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1017\/S1355617716000679","article-title":"Cognitive and social functioning deficits after Anti-N-Methyl-D-aspartate receptor encephalitis: An exploratory case series","volume":"22","author":"McKeon","year":"2016","journal-title":"J Int Neuropsychol Soc"},{"issue":"7","key":"10.3233\/PRM-200677_ref94","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1097\/PHM.0000000000001087","article-title":"Early Functional Outcomes for Pediatric Patients Diagnosed with Anti-N-Methyl-d-Aspartate Receptor Encephalitis during Inpatient Rehabilitation","volume":"98","author":"Howarth","year":"2019","journal-title":"Am J Phys Med Rehabil"},{"issue":"3","key":"10.3233\/PRM-200677_ref95","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1080\/13803395.2017.1329408","article-title":"Cognitive outcomes following anti-N-methyl-D-aspartate receptor encephalitis: A systematic review","volume":"40","author":"McKeon","year":"2018","journal-title":"J Clin Exp Neuropsychol"},{"issue":"4","key":"10.3233\/PRM-200677_ref96","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00415-016-8056-9","article-title":"Cognitive and neuropsychological evolution in children with anti-NMDAR encephalitis","volume":"263","author":"Matricardi","year":"2016","journal-title":"J Neurol"},{"issue":"22","key":"10.3233\/PRM-200677_ref97","doi-asserted-by":"publisher","first-page":"e1997","DOI":"10.1212\/WNL.0000000000005605","article-title":"Long-term neuropsychological outcome following pediatric anti-NMDAR encephalitis","volume":"90","author":"De Bruijn","year":"2005","journal-title":"Neurology"},{"key":"10.3233\/PRM-200677_ref98","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.brainres.2015.12.026","article-title":"Catecholaminergic based therapies for functional recovery after TBI","volume":"1640","author":"Osier","year":"2016","journal-title":"Brain Res"},{"issue":"6","key":"10.3233\/PRM-200677_ref99","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1097\/WCO.0b013e328010944f","article-title":"Pharmacological enhancement of cognitive and behavioral deficits after traumatic brain injury","volume":"19","author":"Tenovuo O","year":"2006","journal-title":"Curr Opin Neurol"},{"issue":"6","key":"10.3233\/PRM-200677_ref100","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1177\/0269215516655590","article-title":"The efficacy and safety of extended-release methylphenidate following traumatic brain injury: A randomised controlled pilot study","volume":"31","author":"Dymowski","year":"2017","journal-title":"Clin Rehabil"},{"issue":"2","key":"10.3233\/PRM-200677_ref101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/HTR.0000000000000432","article-title":"Benefits of Methylphenidate for Long-Term Attention Problems After Traumatic Brain Injury in Childhood","volume":"34","author":"Kurowski","year":"2019","journal-title":"J Head Trauma Rehabil"},{"issue":"9","key":"10.3233\/PRM-200677_ref102","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1038\/npp.2016.261","article-title":"Methylphenidate and memory and attention adaptation training for persistent cognitive symptoms after traumatic brain injury: A randomized, placebo-controlled trial","volume":"42","author":"McDonald","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.3233\/PRM-200677_ref103","doi-asserted-by":"publisher","first-page":"758","DOI":"10.3109\/02699052.2015.1004747","article-title":"Methylphenidate reduces mental fatigue and improves processing speed in persons suffered a traumatic brain injury","volume":"29","author":"Johansson","year":"2015","journal-title":"Brain Inj"},{"issue":"6","key":"10.3233\/PRM-200677_ref104","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1017\/neu.2015.17","article-title":"The effectiveness of dopamine agonists for treatment of neuropsychiatric symptoms post brain injury and stroke","volume":"27","author":"Sami","year":"2015","journal-title":"Acta Neuropsychiatr"},{"key":"10.3233\/PRM-200677_ref105","doi-asserted-by":"publisher","DOI":"10.1152\/jn.1997.77.1.309"},{"issue":"1","key":"10.3233\/PRM-200677_ref106","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ijpsycho.2011.06.022.Alpha-2","article-title":"Alpha-2 Adrenergic Challenge with Guanfacine One Month after Mild Traumatic Brain Injury: Altered Working Memory and BOLD Response","volume":"82","author":"Mcallister","year":"2011","journal-title":"Int J Psychophysiol"},{"issue":"6","key":"10.3233\/PRM-200677_ref107","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1136\/jnnp.2009.195792","article-title":"Attention deficits following ADEM ameliorated by guanfacine","volume":"82","author":"Singh-Curry","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"10.3233\/PRM-200677_ref108","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.biopsych.2006.06.034","article-title":"The Effects of Guanfacine on Context Processing Abnormalities in Schizotypal Personality Disorder","volume":"61","author":"McClure","year":"2007","journal-title":"Biol Psychiatry"},{"issue":"1","key":"10.3233\/PRM-200677_ref109","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1146\/annurev-pharmtox-010715-103617","article-title":"Targeting Prefrontal Cortical Systems for Drug Development: Potential Therapies for Cognitive Disorders","volume":"56","author":"Arnsten","year":"2016","journal-title":"Annu Rev Pharmacol Toxicol"}],"container-title":["Journal of Pediatric Rehabilitation Medicine"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/PRM-200677","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:36:40Z","timestamp":1777610200000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/PRM-200677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,28]]},"references-count":109,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/prm-200677","relation":{},"ISSN":["1874-5393","1875-8894"],"issn-type":[{"value":"1874-5393","type":"print"},{"value":"1875-8894","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,28]]}}}